Pfizer Inc.
COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND IDO1 INHIBITOR FOR THE TREATMENT OF CANCER

Abstract:

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L1 antibody and an IDO1 inhibitor. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 or IDO1 expression.